Evidence map›Paper›PMID 41862680›Full record

Trial reportBritish journal of cancer2026

Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.

Ta-Chen Huang, Jhe-Cyuan Guo, Chia-Chi Lin, Hung-Yang Kuo, Chien-Huai Chuang, Jason Chia-Hsien Cheng, Feng-Ming Hsu, Jang-Ming Lee, Pei-Ming Huang, Cher-Wei Liang and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05130684 (Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05130684 phase2unknown statusnot on this map

Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

TypeinterventionalSponsorNational Taiwan University HospitalRan2021 to 2024Enrolled43ConditionsLocally Advanced Esophageal Squamous Cell CarcinomaArmsNivolumab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ta-Chen HuangGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Jhe-Cyuan GuoDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-6689-9640
Chia-Chi LinDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Hung-Yang KuoGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Chien-Huai ChuangGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-2327-0340
Jason Chia-Hsien ChengGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-2007-0220
Feng-Ming HsuGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Jang-Ming LeeDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Pei-Ming HuangDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Cher-Wei LiangDepartment of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
Yu-I LiDepartment of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
Chih-Hung HsuGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.ORCID http://orcid.org/0000-0003-0495-973X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNivolumab is effective in treating patients with esophageal squamous cell carcinoma (ESCC). The efficacy of nivolumab in combination with neoadjuvant chemoradiotherapy (CRT) remains unclear.

methodsIn this phase II trial with Simon's 2-stage design, neoadjuvant nivolumab, paclitaxel, and cisplatin were administered with radiotherapy followed by esophagectomy to patients with locally advanced ESCC. The primary endpoint was pathological complete response (pCR). The secondary endpoints were feasibility, safety, recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS).

resultsA total of 17 patients were enrolled in stage I. Fourteen patients received esophagectomy, with pCR achieved in 4, below the criterion for continuing to stage II. All grade and ≥grade 3 treatment emergent adverse events (TEAEs) occurred in 15 and 4 patients, respectively. Immune-related TEAEs occurred in 7; none were ≥ grade 3. The median durations of RFS, PFS, and OS were 8, 12, and 25 months, respectively. Patients with high expression of PD-L1 had higher pCR rate (100% vs 18%, P = 0.019).

conclusionsNivolumab in combination with neoadjuvant CRT is safe for patients with locally advanced ESCC, and may be beneficial in those with high PD-L1 expression. CLINICAL

trial registrationNCT05130684.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyNivolumabAdultAgedCisplatinFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPaclitaxelPathologic Complete ResponseCisplatinNivolumabPaclitaxel

Identifiers

PMID41862680
PMCPMC13133124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.